![First-in-human data of [161Tb]Tb-SibuDAB](https://media.licdn.com/dms/image/v2/D4D12AQEkDESd2BYcJQ/article-cover_image-shrink_600_2000/article-cover_image-shrink_600_2000/0/1733732861707?e=2147483647&v=beta&t=l7ieSYHBjDlg4m1L1TMVRSsLa5IlhDyvwJSVp_QHnlI)
First-in-human data of [161Tb]Tb-SibuDAB
First-in-human data suggest [161Tb]Tb-SibuDAB is a promising radiopharmaceutical for the current indication of radioligand therapy in metastatic castration-resistant prostate cancer.
First-in-human data suggest [161Tb]Tb-SibuDAB is a promising radiopharmaceutical for the current indication of radioligand therapy in metastatic castration-resistant prostate cancer.
Head of Radiopharmacy at University Hospital Augsburg
2 个月??
Doctor of Dentistry - DDM|Crafting Smiles with Innovation|Design |Data| Research
2 个月Amazing ????????
General Secretary of Particle Therapy Co-Operative Group (PTCOG)
2 个月Congratulations!
Chief Executive Officer at Amphilix, Entrepreneur, Board Member
2 个月Great results
Having fun with radiation
2 个月amazing, congrats on the ground breaking data